66th ASH Annual Meeting: 702. CAR-T Cell Therapies: Basic and Translational: Poster I

Symposia: CAR-T Cell Therapies: Basic and Translational Oral and Poster Abstracts
Poster

Research, Artificial intelligence (AI), Lymphoid Leukemias, Acute Myeloid Malignancies, ALL, Combination therapy, AML, Fundamental Science, Clinical trials, Adult, Bispecific Antibody Therapy, Lymphomas, CLL, Non-Hodgkin lymphoma, Drug development, Translational Research, Assays, Genomics, Bioinformatics, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Plasma Cell Disorders, B Cell lymphoma, Clinical Research, Hematopoiesis, Diseases, Immune mechanism, Treatment Considerations, Biological therapies, Immunology, Immunotherapy, Aggressive lymphoma, Adverse Events, Lymphoid Malignancies, Computational biology, Biological Processes, Myeloid Malignancies, Emerging technologies, Technology and Procedures, Gene editing, Molecular biology, Study Population, Profiling, Human, Measurable Residual Disease , Animal model, Machine learning, Molecular testing, Natural language processing, Omics technologies

Halls G-H (San Diego Convention Center)

2024

Potent and Effective Targeting of AML with ‘Off-the-Shelf’ Engineered CD45-Targeting CAR T-Cells

Matthew Shaw, PhD¹^*, Aiyin Liao, PhD¹^*, Naeem Khan, PhD²^*, Sylvie D Freeman^3,4, Thomas E. Whittaker, PhD⁵^*, Adrian J. Thrasher, MBBS, PhD⁶^*, Martin Pule⁷^*, Kerry Chester, PhD⁸^*, Jenny Yeung, PhD⁹^* and Persis Amrolia, FRCP, FRCPath, PhD¹⁰^*

¹UCL Great Ormond Street Institute of Child Health, London, GBR
²Institute of Immunology and Immunotherapy, Birmingham, ENG, GBR
³Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom
⁴University of Birmingham, Birmingham, United Kingdom
⁵UCL Great Ormond Street Institute of Child Health, London, United Kingdom
⁶UCL Great Ormond St Institute of Child Health, London, United Kingdom
⁷University College London, London, GBR
⁸UCL Cancer Institute, London, GBR
⁹UCL Great Ormond Street Institute of Child Health, London, ENG, United Kingdom
¹⁰Great Ormond Street Children’s Hospital, London, United Kingdom

2025

Novel CD2-Targeting Trispecific Immune Effector Cell Engager (TRIEC) Coupled with CD19 CAR-T Overcomes Resistant B-Cell Lymphoma

Elijah P Darnell, MD^1,2,3, Hana N Takei³^*, Mark B Leick, MD^1,3^*, Filippo Birocchi, PhD³^*, Amanda A Bouffard³^*, Trisha R Berger, PhD³^* and Marcela V Maus, MD, PhD^1,3

¹Harvard Medical School, Boston, MA
²Dana-Farber Cancer Institute, Boston, MA
³Cellular Immunotherapy Program, Mass General Cancer Center, Massachusetts General Hospital, Boston, MA

2026

Inhibition of PI3Kγ/δ Signaling Promotes an Early Memory State in CAR T Cells and Enhances Their In Vivo Persistence and Efficacy

Alexandra E. Rojek, MD¹, Lishi Xie, PhD²^*, Alan J. Cooper³^*, Xiufen Chen, PhD¹^*, Peter A. Riedell, MD^1,2, Michael R Bishop, MD^1,2 and Justin Kline, MD^1,4

¹Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL
²David and Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago, IL
³Yale School of Medicine, New Haven, CT
⁴University of Chicago, Chicago, IL

2027

Utilization of Therapy-Naïve T Cells to Enhance the Efficacy of CAR-T Cells in the Treatment of B-NHL Patients

Charlotte Junkuhn^1,2,3^*, Phillip Schiele^3,4^*, David Busch⁴^*, Julia Polansky-Biskup^5,6^*, Annette Künkele-Langer^1,7^*, Benedikt Obermayer⁸^*, Lars Bullinger^9,10,11,12, Marco Frentsch^4,6^* and Il-Kang Na^{1,4,6,13,14,15,16,17}^*

¹BSIO Berlin School of Integrative Oncology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
²Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt- Universität zu Berlin, Department of Hematology, Oncology and Cancer Immunology, Berlin, AL, Germany
³Berlin Institute of Health at Charité-Universitätsmedizin Berlin, BIH Center for Regenerative Therapies (BCRT), Berlin, Germany
⁴Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt- Universität zu Berlin, Department of Hematology, Oncology and Cancer Immunology, Berlin, Germany
⁵Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt- Universität zu Berlin, Berlin, Germany
⁶Berlin Institute of Health at Charité – Universitätsmedizin Berlin, BIH Center for Regenerative Therapies (BCRT), Therapy-Induced Remodeling in Immuno-Oncology, Berlin, Germany
⁷Department of Pediatric Oncology and Hematology, Charité - Universitätsmedizin Berlin, Berlin, Germany
⁸Core Unit Bioinformatics - CUBI, Berlin Institute of Health, Berlin, DEU
⁹Department of Internal Medicine III, University of Ulm, Germany, Berlin, DEU
¹⁰German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany
¹¹Department of Hematology, Oncology, Tumor Immunology, Charité University Medicine, Berlin, Germany
¹²University of Ulm, Berlin, Germany
¹³Medical Department of Hematology, Oncology and Tumor Immunology, Molekulares Krebsforschungszentrum (MKFZ), Charité - Universitätsmedizin, Berlin, Germany
¹⁴Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt- Universität zu Berlin, ECRC Experimental and Clinical Research Center, Berlin, Germany
¹⁵German Cancer Consortium (DKTK), Berlin, Germany
¹⁶Experimental and Clinical Research Center, a cooperation between the Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité Universitätsmedizin Berlin, Berlin, Germany
¹⁷Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany

2028

Prediction of Therapeutic Potential of CD19 CAR-T Cells for LBCL By Histone Mark Analyses of Core Epigenetic Programming

Salvatore Fiorenza, MBBS, PhD, BSc, FRACP, FRCPA, MPH¹, Yue Cao, PhD²^*, Ye Zheng, PhD³^*, Janaki Purushe⁴^*, Tamara Bock⁵^*, Erik L Kimble, MD⁶, Derek Janssens, PhD⁷^*, Delaney Kirchmeier, BS⁶^*, Alexandre V. Hirayama, MD⁸, Jordan Gauthier, MD, MSc⁶, David G. Maloney, MD, PhD⁹, Stanley R. Riddell, MD¹⁰, Akira Nguyen-Shaw, PhD¹¹^*, Steven Henikoff, PhD¹²^*, Jean Yang¹³^* and Cameron J. Turtle, MBBS, PhD¹⁴^*

¹Faculty of Medicine and Health, University of Sydney, Balwyn North, VIC, Australia
²Sydney Precision Data Science Centre, University of Sydney, Sydney, Australia
³Bioinformatics and Computational Biology Department, The University of Texas MD Anderson Cancer Center, Houston, TX
⁴Fred Hutchinson, Seattle, WA
⁵Faculty of Medicine and Health, University of Sydney, Camperdown, Australia
⁶Fred Hutchinson Cancer Center, Seattle, WA
⁷Basic Sciences Division, Van Andel Ins, Seattle, WA
⁸Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA
⁹Fred Hutch Cancer Center, University of Washington, Seattle, WA
¹⁰Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA
¹¹Faculty of Medicine and Health, University of Sydney, Camperdown, NSW, Australia
¹²Basic Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA
¹³Sydney Precision Data Science Centre, University of Sydney, Camperdown, NSW, Australia
¹⁴University of Sydney, Sydney, NSW, Australia

2029

iPSC-Derived Chimeric Antigen Receptor T Cells That Originally Lack CD5 Expression Exhibits Robust Cytotoxicity Against T-Cell Malignancies

Ayaka Goto¹^*, Midori Ishii¹^*, Shintaro Kinoshita¹^*, Yoshiki Furukawa¹^*, Norihide Izumi¹^*, Jun Ando^1,2^*, Hiromitsu Nakauchi^3,4^* and Miki Ando¹

¹Department of Hematology, Juntendo University School of Medicine, Tokyo, Japan
²Division of Cell Therapy & Blood Transfusion Medicine, Juntendo University School of Medicine, Tokyo, Japan
³Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford
⁴Stem Cell Therapy Laboratory, Advanced Research Institute, Tokyo Medical and Dental University, Tokyo, Japan

2030

Effector Differentiation and Exhaustion Attenuate on-Target, Off-Tumor Toxicity of CD24 CAR T Cells

Alexander P. Boardman, MD^1,2^*, Adhithi Rajagopalan, PhD³^*, Sophia Chen, MD³^*, Brandon Ng, PhD³^*, Jacob Fischman³^*, Alyssa Massa³^*, Harold K Elias, MD⁴, Dylan Manuele⁴^*, Mohamed I. Atmane⁵^*, Ileana Miranda, DVM, MSc, DACVP⁵^*, Scott E. James, MD, PhD^6,7 and Marcel R.M. van den Brink, MD, PhD^6,8,9

¹Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
²Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY
³Department of Immunology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY
⁴Memorial Sloan Kettering Cancer Center, New York, NY
⁵Center of Comparative Medicine & Pathology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY
⁶Department of Immunology, Sloan Kettering Institute, New York, NY
⁷Department of Medicine, Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY
⁸Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA
⁹Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY

2031

Early MRD Detection after CAR-T Associated with Poor Outcome in Patients with Large B-Cell Lymphoma

Nira Krasnow, MD^1,2,3^*, Katie Maurer, MD, PhD^2,3,4, Catherine Song⁴^*, Timothy Blewett⁵^*, Kan Xiong⁵^*, Andela Crnjac⁶^*, Lily Gao⁴^*, Justin Rhoades⁵^*, Reid W. Merryman, MD^2,7,8, Satyen Gohil, MD PhD⁹^*, Caitlyn Duffy¹⁰^*, Liliana Guerrero²^*, Mikaela M. McDonough¹¹^*, Robert A. Redd, MS¹²^*, Heather Jacene¹³^*, Jamie Dela Cruz¹⁴^*, Justin Budka¹⁵^*, Mike Mattie, PhD¹⁶^*, Brodie Miles, PhD¹⁷^*, Donna S. Neuberg, ScD¹², Philippe Armand, MD, PhD², Catherine J. Wu, MD^2,3,4^*, Viktor Adalsteinsson⁵^* and Caron A. Jacobson, MD, MMSc²

¹Department of Medicine, University of California, San Francisco, San Francisco
²Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
³Harvard Medical School, Boston, MA
⁴Broad Institute of MIT and Harvard, Cambridge, MA
⁵Broad Institute, Boston, MA
⁶Broad Institute, BOSTON, MA
⁷Department of Medical Oncology, Brigham and Women's Hospital, Boston, MA
⁸Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
⁹University College London Hospitals NHS Foundation Trust, London, United Kingdom
¹⁰Department of Medical Oncology, Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA
¹¹Dana-Farber Cancer Institute, Boston, MA
¹²Department of Data Science, Dana-Farber Cancer Institute, Boston, MA
¹³Department of Imaging, Dana-Farber Cancer Institute, Boston, MA
¹⁴Dana Farber Cancer Institute, Boston, MA
¹⁵Kite, A Gilead Company, Santa Monica, CA
¹⁶Kite Pharma, a Gilead company, Santa Monica, CA
¹⁷Kite Pharma, a Gilead Company, Santa Monica, CA

2032

Novel Natural Ligand Chimeric Antigen Receptors (CARs) Targeting CD70 with a Redesigned CD27 Binding Interface Provide Enhanced Potency Against Acute Myeloid Leukemia

Tiffany Que, MS^1,2,3^*, Lucas SP Rudden, PhD^3,4^*, André Sobczyk, PhD^1,3^*, Patrick Barth, PhD^3,4^* and Caroline Arber, MD^2,3,5

¹Department of oncology UNIL-CHUV, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
²University of Lausanne, Lausanne, Switzerland
³Ludwig Institute for Cancer Research, Lausanne, Switzerland
⁴Institute of Bioengineering, Ecole Polytechnique Fédérale Lausanne, Lausanne, Switzerland
⁵Department of oncology UNIL-CHUV, Lausanne University Hospital, Epalinges, Vaud, Switzerland

2033

Tigit: The Potential Mechanisms of Relapse in Multiple Myeloma Following Anti-BCMA CAR-T Therapy and a Promising Target for Improving CAR-T Efficacy

Yuan Xia, MD¹^*, Xuxing Shen²^*, Min Shi³^*, Na Shen³^*, Yu Zhu, MD⁴^*, Lei Fan⁵^*, Jianyong Li, MD⁶ and Lijuan Chen⁷^*

¹Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu Province, China
²Jiangsu Province Hospital, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China
³The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China
⁴Department of Hematology, Jiangsu Provincial People's Hospital, Nanjing, China
⁵Lymphoma Center, Department of Hematology, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
⁶First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China
⁷Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China

2034

Patterns of Immune Reconstitution and Their Clinical Significance in Aggressive Lymphoma Treated with CAR-T Therapy

Danny Luan, MD, MPH¹, Susan DeWolf, MD², Teng Fei, PhD³^*, Sandeep S. Raj, MD⁴, Gunjan L. Shah, MD⁵, Caleb Lareau, PhD⁶^*, Mohammad Alhomoud, MD⁷, Gilles Salles, MD, PhD⁸, Alfredo Rivas-Delgado, MD, PhD⁹, Kai Rejeski, MD¹⁰, Jae H. Park, MD¹¹, Efrat Luttwak, MD⁹, Alejandro Luna, MD, PhD¹²^*, Magdalena Corona, MD, PhD⁴^*, Evangelos Ntrivalas, MD, PhD¹³^*, Giulio Cassanello, MD¹⁴^*, Marina Gomez-Llobell, MD⁴^*, Allison Parascondola, MPH¹⁴^*, Michael Scordo, MD¹⁵, Katharine C. Hsu, MD, PhD⁶, Maria Lia Palomba, MD⁹, Miguel Angel Perales, MD¹⁶ and Roni Shouval, MD, PhD⁴

¹Division of Hematology and Medical Oncology, Department of Medicine and Meyer Cancer Center, Weill Cornell Medicine, New York, NY
²Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
³Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY
⁴Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
⁵Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY
⁶Memorial Sloan Kettering Cancer Center, New York, NY
⁷Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York
⁸Lymphoma Service Chief, Memorial Sloan Kettering Cancer Center, New York, NY
⁹Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
¹⁰Department of Medicine III, LMU University Hospital, Munich, Germany
¹¹Cellular Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY
¹²Unidad de trasplante y terapia celular, Hospital Universitario Ramon y Cajal, Madrid, Spain
¹³Hematopathology Service, Memorial Sloan Kettering Cancer Center, New York
¹⁴Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
¹⁵Transplant and Cellular Therapy Services, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, NY
¹⁶Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

2035

CRG-023 Is a Novel Tri-Specific CAR T Product Candidate Engineered to Prevent Antigen Escape and Sustain Durable Anti-Tumor Functionality Against B-Cell Malignancies

Idit Sagiv Barfi, PhD¹, Eric Liao¹^*, Michael S Mannon²^*, Boi Quach²^*, Lingyan Wang²^*, Samantha Koo-McCoy²^*, Michael C Yi²^*, James S Byers III²^*, Nhung Nguyen²^*, Trevor M Bentley²^*, Savannah Yung³^*, Yu Huang²^*, Michael T Bethune²^*, Matthew Siegel²^* and Michael O Ports²^*

¹Cargo Therapeutics, San Carlos, CA
²Cargo Therapeutics, San Carlos
³Cargo Therapeutics, San Calos

2036

Structure Guided Design of CCL27 CAR T-Cells Against CCR10 for Multiple Myeloma

Nikhil Chilakapati¹^*, Bonell Patino-Escobar, MD¹^*, Jonathan deMontagnac^1,2^*, Haley Johnson³^*, Emilio Ramos, MD, PhD⁴, Paul Phojanakong, BA⁵^*, Fernando Salangsang⁵^*, Veronica Steri, PhD⁵^*, William J Karlon, MD, PhD¹^* and Arun P Wiita, MD, PhD³

¹Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA
²College of the Holy Cross, Worcester, MA
³Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA
⁴Department of Laboratory Medicine, University of California San Francisco, ALAMEDA, CA
⁵Preclinical Therapeutics Core, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA

2037

Development of a Dual-Antigen Targeting CAR-T Therapy Directed Against CD70 and Active Integrin β2 for Acute Myeloid Leukemia

Amrik S Kang^1,2^*, Haley Johnson³^*, Nabeel Razi⁴^*, Nicole Lei⁴^*, Aaron C. Logan, MD, PhD⁴, Benjamin J Huang, MD⁵ and Arun P Wiita, MD, PhD³

¹Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA
²Medical Scientist Training Program, University of California, San Francisco, San Francisco, CA
³Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA
⁴Department of Medicine, Division of Hematology and Oncology, University of California, San Francisco, San Francisco, CA
⁵Department of Pediatrics, University of California, San Francisco, San Francisco, CA

2038

Armored Multivalent CAR-T Cells Targeting BCMA, GPRC5D, and CD38 Eradicate Antigen-Heterogeneous Multiple Myeloma, Address Antigen Escape and Enhance Expansion

Jincai Zhou¹^*, Xinran Luo²^*, Bixia Lei¹^*, Kai Wu²^*, Feifei Shi²^*, Yuting Zhang¹^*, Jingyi Yu²^*, Hong Ma, MD³, Zhe (Joy) Zhou⁴^* and Xiaowen He¹^*

¹R & D, OriCell Therapeutics Co.,Ltd, Shanghai, China
²R & D, Shanghai Yihe Shiji Pharmaceutical Co., Ltd., Shanghai, China
³ORICELL THERAPEUTICS INC, Dover
⁴Shanghai Yihe Shiji Pharmaceutical Co., Ltd., Shanghai, China

2039

Reprogramming T Cell EZH2 to Counteract CAR T Cell Dysfunction during Tumor Control

Mimi Chen, PhD¹^*, Wenbin Mo, MMSc¹^*, Gennaro Clando²^*, Yuanyuan Tian, PhD¹^*, Ciril Abraham, BS^1,3^*, Qingrong Huang^1,4^*, Ying WANG¹^*, Morgan Chaunzwa¹^*, Yan Zhou, MS⁵^*, Andrew Ip, MD, MSc⁶, Andre Goy, MD, MS⁶, Jaroslav Jelinek²^*, Jozef Madzo²^*, Jean-Pierre Issa²^* and Yi Zhang, MD, PhD¹

¹Center for Discovery and Innovation, Hackensack University Medical Center, Nutley, NJ
²Coriell Institute for Medical Research, Camden, NJ
³Fels Institute and Department of Cancer Cellular Biology, Lewis Katz School of Medicine, Temple University, Philadelphia, PA
⁴Clinical Immunology Core, Center for Discovery and Innovation, Hackensack University Medical Center, Nutley, NJ
⁵Fox Chase Cancer Center, Temple University, Philadelphia
⁶Lymphoma Division, John Theurer Cancer Center, Hackensack Meridian Health, Hackensack, NJ

2040

CAR T Cells Accelerate Disease Progression in AMLs Harboring an Inflammatory Transcriptional Signature

Anand S Bhagwat, MD, PhD^1,2, Maksim Shestov³^*, Olga Shestova, PhD³^* and Saar Gill, MD, PhD^3,4

¹Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA
²Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA
³Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
⁴School of Medicine, Division of Hematology/Oncology, University of Pennsylvania, Philadelphia, PA

2041

Tandem CAR-T-Cell Therapy Targeting CD5 and CD7: Facilitating Condition-Free Engraftment of Epitope-Edited Allogeneic HSCs

Guo-Ling Wang^1,2^*, Ting Wang^1,2^*, Jing-Li Han¹^*, Li-Xin Wu^1,2^*, Xuan-Zhong Chen^1,2^*, Zhuo-Yu An¹^*, Chen-Cong Wang¹^*, Peng Zhao¹^*, Lu-Lu Wang¹^*, Mengtong Zang, MS¹^*, Wei Zheng³^*, Hai-Xia Fu¹^*, Jia Feng⁴^*, Hong-Yu Zhang⁴^* and Xiaohui Zhang¹

¹Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China
²Department of Hematology, Peking University Shenzhen Hospital, Shenzhen Peking University-The Hong Kong University of Science and Technology Medical Center, Shenzhen, China
³Cell Therapy Center, Peking University Shenzhen Hospital, Shenzhen, China
⁴Department of Hematology, Peking University Shenzhen Hospital, Shenzhen, China

2042

CTLA-4-Based Activation Inducible Costimulatory Receptors Endow CAR-T Cells with Safe, Tumor-Restricted, Multi-Targeting and Increased Persistence

Afroditi Katsarou^*, Georgios Kladis^*, Alexandros Nianias^*, Jiaxian Wang^*, Thomas Baardemans^*, Ruud Ruiter^*, Marie José Kersten^*, Sonja Zweegman, MD, PhD, Tuna Mutis, MD PhD^*, Richard Groen^* and Maria Themeli, MD, PhD^*

Department of Hematology, Amsterdam UMC-location VUmc, Cancer Center Amsterdam, Amsterdam, Netherlands

2043

Generation of Functional iPSC-Derived CAR-T Cells for Cancer Immunotherapy Via G9a/GLP Inhibition

Ran Jing¹^*, Marcelo Falchetti, Ph.D.²^*, Tianxiao Han³^*, Mohamad Najia, PhD⁴^*, Luca Hensch⁵^*, Eleanor Meader, PhD²^*, Martin Kononov²^*, Stephanie Wang²^*, Caroline Kubaczka, PhD⁶^*, Edroaldo Lummertz Da Rocha, PhD⁷^*, Robert Grant Rowe, MD, PhD⁸, Thorsten M. Schlaeger, PhD¹^*, Marcela Maus, MD⁹, Trista E. North, PhD¹⁰, Leonard I. Zon, MD^11,12 and George Q. Daley, MD, PhD¹

¹Stem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA
²Stem Cell Program, Boston Children's Hospital and Harvard Medical School, Boston
³Stem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital and Dana Farber Cancer Institute, Boston, MA
⁴Harvard Medical School/Boston Children's Hospital, Boston, MA
⁵Stem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital; Harvard Medical School; Harvard University, Boston, MA
⁶Stem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital and Dana Farber Cancer Institute; Harvard Medical School; Harvard University, Boston, MA
⁷Federal University of Santa Catarina, Florianopolis, BRA
⁸Department of Hematology/Oncology, Harvard Medical School/Boston Children's Hospital, Boston, MA
⁹Harvard Medical School, Lexington, MA
¹⁰Stem Cell Program, Boston Children's Hospital, Harvard Medical School, Boston, MA
¹¹Stem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital; Howard Hughes Medical Institute; Harvard Medical School; Harvard Stem Cell Institute; Harvard University, Boston, MA
¹²Howard Hughes Medical Institute, Boston, MA

2044

Molecular Tumor Burden and Clonal Evolution As Factors Associated with Early Progression in Large B-Cell Lymphomas Treated with CAR-T Therapy

Carolina Martinez-Laperche, PhD^1,2^*, Gonzalo Del Campo-Balguerias³^*, Ismael De La Iglesia San Sebastián^2,4^*, Juan Carlos Triviño⁵^*, Francisco Diaz Crespo⁶^*, Rebeca Bailen^2,4^*, Raquel Fernandez-Gonzalez⁷^*, Sara Fernandez-de Córdoba⁸^*, Ana Jiménez Ubieto⁹^*, Alejandro Martín-Muñoz⁹^*, Paula Fernández Caldas-González¹⁰^*, Ignacio Gómez-Centurión, MD^2,4^*, Mi Kwon, MD, PhD^11,12, Javier Anguita^2,4^*, Ramon García-Sanz, MD, PhD¹, Ismael Buño¹³^* and Mariana Bastos-Oreiro^4,14^*

¹Department of Hematology, Hospital General Universitario Gregorio Marañón, Madrid, Spain
²General University Hospital Gregorio Marañón, Madrid, Spain
³Hospital Universitario Clínico mADRID, Madrid, Spain
⁴Health Research Institute Gregorio Marañón, Madrid, Spain
⁵Sistemas Genómicos, Valencia, Spain
⁶Hospital General Universitario Gregorio Marañón, Madrid, Spain
⁷Instituto de Investigación sanitaria Gregorio Marañón, Madrid, Spain
⁸Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain
⁹Department of Hematology, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), CNIO, CIBERONC, Madrid, Spain
¹⁰Hematology Department, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain
¹¹Department of Hematology, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain
¹²Institute of Health Research Gregorio Marañon, Madrid, Spain
¹³Hospital General Universitario Gregorio MarañóN. Instituto De Inve, Madrid, Ma, ESP
¹⁴Hematology Department, General University Hospital Gregorio Marañón, Madrid, Spain

2045

A Layered Cloaking Strategy to Generate Allogeneic iPSC-Derived CD8 T-Cells That Evade NK Clearance

Siddarth Chandrasekaran¹^*, Vignesh Janardhanam²^*, Ian Cardle²^*, Justin Yoo³^*, Yue Zhang-Wong²^*, Julia Bershadsky⁴^*, Elisa Martinez⁴^*, April Marple⁴^*, Laxsha Thaya⁴^*, Charlie Liu⁴^*, Dhanya Vijayan⁴^*, Leanne Jamieson⁴^*, Lifu Sheng⁴^*, Elizabeth Csaszar⁴^*, Emily Titus⁴^* and Chris Bond²

¹Notch Therapeutics, Seattle, WA
²Notch Therapeutics, Seattle
³Notch Therapeutics, Everett, WA
⁴Notch Therapeutics, Toronto, Canada

2046

Nonclinical Toxicology, Biodistribution, and Pharmacokinetics of UB-VV111, an In Vivo Anti-CD19 CAR T Cell Therapy

Alissa H. Brandes¹^*, Angela Soo Min Koo, BSc¹^*, Anai Perez¹^*, Kathryn Michels, PhD¹^*, Travis Friesen, PhD¹^*, Alyssa Sheih, PhD¹^*, Don Parilla²^*, Susana Hernandez¹^*, Nolan Ericson, BSc¹^*, Sarah Dickerson, PhD²^*, Mason Muhonen²^*, Jessica Freeman²^*, Sarah Gould²^*, Alessandra Maria Sullivan, PhD²^*, Jeffrey Teoh, PhD¹^*, Byoung Y. Ryu, PhD¹, Andrew M. Scharenberg, MD¹^* and Ryan P. Larson, PhD¹^*

¹Umoja Biopharma, Seattle, WA
²Umoja Biopharma, seattle, WA

2047

Enabling Potent T Cell Delivery and Mitigating Key Off-Target Concerns of In Vivo

CAR T Lentiviral Vectors with the Targeted Paramyxovirus Fusogen System

Shirisha Amatya, MS¹^*, Jesse Green, PhD¹^*, Chi-Shuen Chu, PhD²^*, Adam Hilterbrand, PhD²^*, Reuben Burch¹^*, Chris Baldeviano, PhD³^*, Edward Rebar, PhD⁴^*, Terry J Fry, MD¹, Albert Ruzo, PhD¹^*, Kutlu G Elpek, PhD⁵^* and Kyle Trudeau, PhD⁵^*

¹Sana Biotechnology, Seattle, WA
²Sana Biotechnology, Seattle
³Sana Biotechnology, Cambridge
⁴Sana Biotechnology, Richmond, CA
⁵Sana Biotechnology, Cambridge, MA

2048

Optimizing CAR Costimulatory Domains Using Contrastive Learning and Optimal Transport on High-Throughput Screening Data

Conor Kelly, MSc¹^*, Wenjun Zhu, MD, PhD²^*, Keyvan Keyvanfar³^*, Pradeep Dagur, PhD⁴^* and Stefan Cordes, MD, PhD⁵

¹Georgetown University School of Medicine, Washington, DC
²Thoracic and GI Malignancies Branch, National Cancer Institute, National Institutes of Health (NIH), Bethesda, MD
³National Heart Lung and Blood Institutes, National Institutes of Health, Bethesda, MD
⁴Flow Cytometry Core, National Heart Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda, MD
⁵Translational Stem Cell Biology Branch, Lung and Blood Institute, National Institutes of Health, Bethesda, MD

2049

Optimizing the IFNγ Axis Improves CAR T-Cell Potency in AML but Not B-ALL

Nat Murren, B.S.¹^*, Isaac King²^*, Lauren Mahoney¹^*, Paresh Vishwasrao³^*, Jessica Kain, MS¹, Morgan Antti¹^*, Luke Kalcheim¹^* and Rebecca M Richards, MD, PhD^4,5,6

¹University of Wisconsin-Madison, Madison, WI
²University of Wisconsin Madison, Madison, WI
³Division of Pediatric Hematology, Oncology, and Bone Marrow Transplantation, University of Wisconsin-Madison, Madison
⁴University of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, Madison, WI
⁵Wisconsin Blood Cancer Research Institute, University of Wisconsin-Madison, Madison, WI
⁶Department of Pediatrics, University of Wisconsin-Madison, MADISON, WI

2050

Potent Target-Specific Efficacy of CAR T Cells Directed Toward the AML and KMT2A-Rearranged Specific Antigen CLEC2A

Danielle C. Kirkey, MD^1,2, Grace Hawkins¹^*, Melia Blankenfeld, BS¹^*, Isabel Lira, BS¹^*, Nika Panahi, BS¹^*, Margaret G Hines³^*, Seungmin Shin³^*, Tiffany Hylkema, BS¹^*, Cyd McKay¹^*, Christina Root¹^*, Logan K. Wallace, MSc¹^*, Jack H. Peplinski, MSc¹^*, Rhonda E. Ries, MA¹^*, Concetta Quintarelli, PhD⁴^*, Franco Locatelli, MD⁴, Wei Li, PhD³^* and Soheil Meshinchi, MD, PhD¹

¹Translational Science and Therapeutics, Fred Hutchinson Cancer Center, Seattle, WA
²Pediatric Hematology/Oncology, Seattle Children's Hospital, Seattle, WA
³Division of Infectious Diseases, University of Pittsburgh, Pittsburgh, PA
⁴IRCCS Bambino Gesù Children's Hospital, Rome, Italy

2051

Deciphering the Impact of Immunological Aging in CLL CAR T Cell Therapy

Julia Han Noll^1,2,3^*, Humza Hemani⁴^*, Jiang Yuan Li, PhD⁴^*, Kevin R. Amses, PhD^3,5,6^*, Bruce Levine, PhD^2,3,7, Carl H. June, MD^2,3,8,9, Nan-Ping Weng, PhD⁴^* and Joseph A. Fraietta, PhD^3,5,10^*

¹Department of Microbiology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA
²Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA
³Parker Institute for Cancer Immunotherapy, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA
⁴National Institute On Aging, National Institutes of Health, Baltimore, MD
⁵Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
⁶Department of Microbiology, University of Pennsylvania, Philadelphia, PA
⁷Department of Pathology and Laboratory Medicine, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA
⁸Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA
⁹Abramson Cancer Center, Department of Medicine, Division of Hematology-Oncology, University of Pennsylvania, Philadelphia, PA
¹⁰Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

2052

All-Trans Retinoic Acid Enhances CS1-BCMA Dual-Target CAR-T Cells in Multiple Myeloma

Yinqiang Zhang^1,2^*, Wu Zhuolin^1,2^*, Wenjing Luo^1,2^*, Chenggong Li^1,2^* and Heng Mei^1,2^*

¹Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
²Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan, China

2053

CAR-T Cell Subsets and Immune Repertoire Are Associated with Immune-Related Adverse Events and Efficacy after CD19 CAR T-Cell Therapy in B Cell Lymphoma

David M Foureau¹, Fei Guo, PhD¹^*, Erik Broemsen, PhD¹^*, Tahj Jones¹^*, Anna Ivanina-Foureau, PhD¹^*, Ryan Jacobs², Bei Hu, MD², Tamara K Moyo, MD²^*, Yifan Pang, MD², Steven I. Park, MD^2,3, Lawrence J. Druhan, PhD⁴, Ariel Bell, MPH⁴^* and Nilanjan Ghosh, MD, PhD²

¹Levine Cancer Institute, Atrium Health, Charlotte, NC
²Department of Hematologic Oncology and Blood Disorders, Atrium Health Levine Cancer Institute, Charlotte, NC
³Wake Forest University School of Medicine, Charlotte, NC
⁴Hematology Oncology Translational Research Laboratory, Atrium Health Levine Cancer Institute, Charlotte, NC

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

702.P1.92 702. CAR-T Cell Therapies: Basic and Translational: Poster I